文献速递白血病造血干细胞移植与细胞治疗

KIR3DL1/HLA-B亚型决定造血细胞移植后急性髓系白血病复发

KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
PubMed 文献 · J Clin Oncol · 2017-05-18

研究基于多态性驱动的表达水平与特异性算法,在体外预测并验证KIR3DL1/HLA-B亚型组合对自然杀伤(NK)细胞抑制与细胞毒潜能的影响,并分析1,328例接受9/10或10/10 HLA相合无关供者造血细胞移植的急性髓系白血病(AML)患者。结果显示,预测为弱抑制或非抑制的KIR3DL1/HLA-B亚型组合与显著更低的复发(HR 0.72;P = .004)和总死亡(HR 0.84;P = .030)相关。

要点

  • KIR3DL1/HLA-B亚型组合可预测NK细胞对AML的抑制强度与细胞毒潜能。
  • 弱抑制或非抑制组合与更低复发(HR 0.72;P = .004)和总死亡(HR 0.84;P = .030)相关。
  • 在高危全部KIR配体组中,弱抑制或非抑制组合的复发HR 0.54(P < .001)、死亡HR 0.74(P < .008)。

核心结论

  • 在HLA相合造血细胞移植的供者选择中考虑KIR3DL1介导的抑制,可能获得更优的移植物抗白血病效应、降低复发风险并提高AML患者生存。

研究设计与样本

  • 基于多态性驱动的表达水平与特异性算法,在体外预测并检测KIR3DL1/HLA-B亚型组合的抑制性与细胞毒性NK潜能。
  • 评估1,328例接受9/10或10/10 HLA相合无关供者造血细胞移植的AML患者。

主要发现

  • 按KIR3DL1亚型分离,NK细胞对具有明确HLA-B亚型的靶细胞呈现可重复的强抑制、弱抑制或非抑制模式,并转化为对AML的离散细胞毒层级。
  • 预测为弱抑制或非抑制的KIR3DL1/HLA-B亚型组合与强抑制组合相比,复发显著更低(HR 0.72;P = .004),总死亡显著更低(HR 0.84;P = .030)。
  • 在全部KIR配体的高危患者组中,弱抑制或非抑制组合的效应最大:复发HR 0.54(P < .001),死亡HR 0.74(P < .008)。
  • 弱抑制和非抑制KIR3DL1/HLA-B亚型组合的益处与供者活化性KIR2DS1的益处相互独立且相加。

关键数值与推荐

  • 弱抑制或非抑制KIR3DL1/HLA-B亚型组合 vs 强抑制组合:复发HR 0.72(P = .004),总死亡HR 0.84(P = .030)。
  • 全部KIR配体的高危组中,弱抑制或非抑制组合 vs 强抑制组合:复发HR 0.54(P < .001),死亡HR 0.74(P < .008)。

临床怎么用

  • 作者认为,在HLA相合造血细胞移植的供者选择中考虑KIR3DL1介导的抑制,可能获得更优的移植物抗白血病效应、降低复发风险并提高AML患者生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Disease relapse remains a major challenge to successful outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT). Donor natural killer (NK) cell alloreactivity in HCT can control leukemic relapse, but capturing alloreactivity in HLA-matched HCT has been elusive. HLA expression on leukemia cells-upregulated in the post-HCT environment-signals for NK cell inhibition via inhibitory killer immunoglobulin-like (KIR) receptors and interrupts their antitumor activity. We hypothesized that varied strengths of inhibition among subtypes of the ubiquitous KIR3DL1 and its cognate ligand, HLA-B, would titrate NK reactivity against acute myelogenous leukemia (AML). Patients and Methods By using an algorithm that was based on polymorphism-driven expression levels and specificities, we predicted and tested inhibitory and cytotoxic NK potential on the basis of KIR3DL1/HLA-B subtype combinations in vitro and evaluated their impact in 1,328 patients with AML who underwent HCT from 9/10 or 10/10 HLA-matched unrelated donors. Results Segregated by KIR3DL1 subtype, NK cells demonstrated reproducible patterns of strong, weak, or noninhibition by target cells with defined HLA-B subtypes, which translated into discrete cytotoxic hierarchies against AML. In patients, KIR3DL1 and HLA-B subtype combinations that were predictive of weak inhibition or noninhibition were associated with significantly lower relapse (hazard ratio [HR], 0.72; P = .004) and overall mortality (HR, 0.84; P = .030) compared with strong inhibition combinations. The greatest effects were evident in the high-risk group of patients with all KIR ligands (relapse: HR, 0.54; P < .001; and mortality: HR, 0.74; P < .008). Beneficial effects of weak and noninhibiting KIR3DL1 and HLA-B subtype combinations were separate from and additive to the benefit of donor activating KIR2DS1. Conclusion Consideration of KIR3DL1-mediated inhibition in donor selection for HLA-matched HCT may achieve superior graft versus leukemia effects, lower risk for relapse, and an increase in survival among patients with AML.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Boudreau JE, Giglio F, Gooley TA, et al. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol. 2017. PMID: 28520526. doi:10.1200/JCO.2016.70.7059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。